Table 1 TMB did not impact Vigil efficacy in BRCAwt patients.

From: Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

 

BRCAwt/High TMB

BRCAwt/Low TMB

 

Vigil n = 33

Vigil n = 14

 

Placebo n = 34

Placebo n = 10

OS

HR = 0.598 90% CI 0.354–1.011 p = 0.052

HR = 1.011 90% CI 0.405–2.524

RFS

HR = 0.514 90% CI 0.252–1.051 p = 0.06

HR = 1.153 90% CI 0.244–5.461

Back to article page